Asset Details
Do you wish to reserve the book?
Discovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Discovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
Do you wish to request the book?
Discovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Discovery of Novel GPVI Receptor Antagonists by Structure-Based Repurposing
2014
Overview
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin. Although effective, these drugs carry risks of increased bleeding and drug 'resistance', underpinning a drive for new antiplatelet agents. To discover such drugs, one strategy is to identify a suitable druggable target and then find small molecules that modulate it. A good and unexploited target is the platelet collagen receptor, GPVI, which promotes thrombus formation. To identify inhibitors of GPVI that are safe and bioavailable, we docked a FDA-approved drug library into the GPVI collagen-binding site in silico. We now report that losartan and cinanserin inhibit GPVI-mediated platelet activation in a selective, competitive and dose-dependent manner. This mechanism of action likely underpins the cardioprotective effects of losartan that could not be ascribed to its antihypertensive effects. We have, therefore, identified small molecule inhibitors of GPVI-mediated platelet activation, and also demonstrated the utility of structure-based repurposing.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Aspirin
/ Bleeding
/ Cardiotonic Agents - chemistry
/ Cardiotonic Agents - pharmacology
/ Collagen
/ Drugs
/ Genetics
/ Humans
/ Kinases
/ Medicine and Health Sciences
/ Molecular Docking Simulation
/ Platelet Membrane Glycoproteins - antagonists & inhibitors
/ Platelet Membrane Glycoproteins - chemistry
/ Platelet Membrane Glycoproteins - metabolism
/ Proteins
/ R&D
/ Severe acute respiratory syndrome
/ Small Molecule Libraries - chemistry
